Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

被引：33

作者：

Ye, Peng ^{[1
]}

Chi, Xiaoxia ^{[2
,3
]}

Cha, Jong-Ho ^{[1
]}

Luo, Shahang ^{[1
]}

Yang, Guanghui ^{[1
]}

Yan, Xiuwen ^{[1
]}

Yang, Wen-Hao ^{[1
,4
]}

机构：

[1] Guangzhou Med Univ, Key Lab Cell Homeostasis, Canc Res Guangdong Higher Educ Inst, Affiliated Canc Hosp & Inst, Guangzhou 910095, Peoples R China

[2] Inha Univ, Grad Sch, Dept Biomed Sci & Engn, Incheon 22212, South Korea

[3] Inha Univ, Dept Biomed Sci, Coll Med, Incheon 22212, South Korea

[4] China Med Univ, Grad Inst Biomed Sci, Taichung 406040, Taiwan

来源：

CELLS | 2021年 / 10卷 / 12期

基金：

中国国家自然科学基金; 新加坡国家研究基金会;

关键词：

E3 ubiquitin ligase; cancer immunotherapy; immune checkpoints; immune signaling pathway; NF-KAPPA-B; MHC CLASS-II; SMALL-MOLECULE INHIBITORS; TARGETED PROTEIN-DEGRADATION; APOPTOSIS IAP PROTEINS; DENDRITIC CELLS; T-CELLS; ANTIGEN PRESENTATION; CBL-B; SELECTIVE DEGRADATION;

D O I：

10.3390/cells10123309

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Cancer immunotherapies, including immune checkpoint inhibitors and immune pathway-targeted therapies, are promising clinical strategies for treating cancer. However, drug resistance and adverse reactions remain the main challenges for immunotherapy management. The future direction of immunotherapy is mainly to reduce side effects and improve the treatment response rate by finding new targets and new methods of combination therapy. Ubiquitination plays a crucial role in regulating the degradation of immune checkpoints and the activation of immune-related pathways. Some drugs that target E3 ubiquitin ligases have exhibited beneficial effects in preclinical and clinical antitumor treatments. In this review, we discuss mechanisms through which E3 ligases regulate tumor immune checkpoints and immune-related pathways as well as the opportunities and challenges for integrating E3 ligases targeting drugs into cancer immunotherapy.

引用

页数：34

共 50 条

[21] E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies
Wang, Maoyu
Zhang, Zhensheng
Li, Zhizhou
Zhu, Yasheng
Xu, Chuanliang
FRONTIERS IN IMMUNOLOGY, 2023, 14
[22] E3 ubiquitin ligases in the acute leukemic signaling pathways
Zhan, Qianru
Zhang, Heyang
Wu, Boquan
Zhang, Naijin
Zhang, Lijun
FRONTIERS IN PHYSIOLOGY, 2022, 13
[23] Approaches to Discovering Drugs that Regulate E3 Ubiquitin Ligases
Huang, J.
Tsvetkov, L.
Qu, K.
Daniel-Issakani, S.
Payan, D. G.
UBIQUITIN SYSTEM IN HEALTH AND DISEASE, 2009, 1 : 153 - 170
[24] E3 ubiquitin ligases in T-cell tolerance
Paolino, Magdalena
Penninger, Josef M.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (09) : 2337 - 2344
[25] The role of E3 ubiquitin ligases in the development and progression of glioblastoma
Humphreys, Luke M.
Smith, Paul
Chen, Zhuoyao
Fouad, Shahd
D'Angiolella, Vincenzo
CELL DEATH AND DIFFERENTIATION, 2021, 28 (02) : 522 - 537
[26] E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies
Zhou, Zijian
Zheng, Kaifeng
Zhou, Shao
Yang, Youxiong
Chen, Jun
Jin, Xiaofeng
JOURNAL OF MOLECULAR MEDICINE-JMM, 2023, 101 (12): : 1543 - 1565
[27] The many faces of β-TrCP E3 ubiquitin ligases:: reflections in the magic mirror of cancer
Fuchs, SY
Spiegelman, VS
Kumar, KGS
ONCOGENE, 2004, 23 (11) : 2028 - 2036
[28] Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, Khai M.
Busino, Luca
SEMINARS IN CANCER BIOLOGY, 2020, 67 : 53 - 60
[29] A novel family of membrane-bound E3 ubiquitin ligases
Ohmura-Hoshino, Mari
Goto, Eiji
Matsuki, Yohei
Aoki, Masami
Mito, Mari
Uematsu, Mika
Hotta, Hak
Ishido, Satoshi
JOURNAL OF BIOCHEMISTRY, 2006, 140 (02) : 147 - 154
[30] The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases
Nathan, James A.
Lehner, Paul J.
EXPERIMENTAL CELL RESEARCH, 2009, 315 (09) : 1593 - 1600

← 1 2 3 4 5 →